Daniel Hochdorfer
Papers
1
Total Citations
30
H-Index
1
About
Daniel Hochdorfer is a virologist whose work centers on advancing the quantitative analysis of viral therapeutics. His primary research areas include virus-based therapeutics, viral titer determination, and the development of automated, label-free assays for infectious disease research. Hochdorfer's most significant contribution is the creation of a novel, automated, label-free TCID50 assay, which provides a more efficient and reproducible method for determining the infectious titer of virus-based therapeutics. This work, published in 2021 and cited 30 times, addresses a critical bottleneck in the production and quality control of viral vectors used in gene therapy and vaccine development. By eliminating the need for manual, labor-intensive steps and subjective endpoint interpretation, Hochdorfer's assay enhances throughput and accuracy, directly supporting the scalable manufacturing of viral therapeutics. His research is particularly impactful for the biopharmaceutical industry, where precise viral titer measurement is essential for product consistency and regulatory approval. Hochdorfer's contributions are paving the way for more robust and standardized approaches in virology, with implications for the development of next-generation vaccines and gene therapies.
Research Focus
Key Achievements
Top Papers
- 1